Apalutamide clinical trials
Also written ARN-509, JNJ-56021927 and Erleada.
How each study uses apalutamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the apalutamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Feb 2018 · ERLEADA · NDA 210951 (FDA, Drugs@FDA)
- European Union
- 14 Jan 2019 · Erleada · EMEA/H/C/004452 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
85 studies that test it; most in 2020 (13)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 8 |
| 2019 | 9 |
| 2020 | 13 |
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 54
Aragon Pharmaceuticals, Inc. (15) · Janssen Research & Development, LLC (8) · M.D. Anderson Cancer Center (6) · Dana-Farber Cancer Institute (4) · Janssen Pharmaceutical K.K. (3) · NRG Oncology (3) · University of Washington (3) · Jonsson Comprehensive Cancer Center (2)
Often tested with
Tested in the same studies.
Abiraterone (16) · Abiraterone Acetate (13) · Prednisone (8) · Enzalutamide (5) · Antiandrogen Therapy (4) · Docetaxel (4) · Gonadotropin-releasing Hormone Analog (3) · Bicalutamide (3)
Related medicines
As reviewed, each with the page that says it.
- One of Antiandrogens source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10, 5 in phase 3
Studies that test apalutamide, phase 3 first.
- Nov 2026Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialPhase 3 · NRG Oncology
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Dec 2026A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyPhase 3 · Janssen Research & Development, LLC
- Mar 2027An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASPhase 3 · Aragon Pharmaceuticals, Inc.
- Jun 2027PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.Phase 3 · M.D. Anderson Cancer Center
- Dec 2026Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialPhase 2 · Jonsson Comprehensive Cancer Center
- Dec 2026Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Jan 2027Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Apr 2027A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerPhase 1 · Astellas Pharma Global Development, Inc.
- Jun 2027Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase 2 · University of British Columbia
Studies
Open first, then newest update. How each study uses apalutamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 85
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Apalutamide
- A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07783282Written as apalutamide
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Apalutamide 60mg Tab
- PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.RecruitingPhase 3M.D. Anderson Cancer CenterNCT06274047Written as Apalutamide
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT06067269Written as Apalutamide
- TherApeutics in Early ProState Cancer (TAPS02)RecruitingPhase 2Cambridge University Hospitals NHS Foundation TrustNCT05191680Written as Apalutamide Oral Tablet [Erleada]
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Apalutamide
- Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PETRecruitingPhase 2Marco OderdaNCT06758882Written as Apalutamide
- An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate CancerRecruitingNot applicableZhujiang HospitalNCT04997252Written as Apalutamide
- Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone MetastasesRecruitingNot applicableZhujiang HospitalNCT05740488Written as Apalutamide
- Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RPRecruitingPhase 2Cancer Research AntwerpNCT03899077Written as Apalutamide
- Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)Not yet recruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05778097Written as Apalutamide 60mg Tab
- Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT TreatmentNot yet recruitingPhase 2Fudan UniversityNCT05717582Written as apalutamide
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05406999Written as Apalutamide
- Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in JapanRecruitingPhase 4Kindai UniversityNCT04601441Written as Apalutamide
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerCompletedPhase 3Alliance Foundation Trials, LLC.NCT03009981Written as Apalutamide
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPCActive, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02489318Written as Apalutamide
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02257736Written as Apalutamide
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingPhase 2Janssen Pharmaceutical K.K.NCT04325828Written as Apalutamide
- A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03767244Written as Apalutamide
See all 85 studies that test apalutamide →
Given beside what is tested · 23 — apalutamide is usual care or a partner of the new treatment
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04423211Written as Apalutamide
- Study of Oral MRT-2359 With Apalutamide in Prostate CancerRecruitingPhase 2Monte Rosa Therapeutics, IncNCT07745361Written as Apalutamide
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT06095089Written as Apalutamide
- Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06931340Written as Apalutamide
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Apalutamide
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as Apalutamide
- Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancRecruitingPhase 2Edwin Posadas, MDNCT05534646Written as AR Blockade
- Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate CancerRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT07002320Written as Apalutamide
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingPhase 3Canadian Cancer Trials GroupNCT06592924Written as Apalutamide
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Written as Apalutamide
- Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.RecruitingPhase 3Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDNCT07333066Written as Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerActive, not recruitingPhase 2/3VA Office of Research and DevelopmentNCT04787744Written as ADT + Apalutamide
- ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04662580Written as Apalutamide
- Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05751941Written as Apalutamide
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic AdenocarcinomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03436654Written as Apalutamide
- A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for MetastasesCompletedPhase 2Janssen Research & Development, LLCNCT04523207Written as Apalutamide
- Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerTerminatedPhase 2Rahul AggarwalNCT04926181Written as Apalutamide
- A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)TerminatedPhase 1Janssen Research & Development, LLCNCT05295927Written as Apalutamide
- ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone AcetateCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02106507Written as apalutamide
Showing 20 of 23.
As the comparator · 2 — what is tested is compared with apalutamide
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as Apalutamide
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingPhase 2Sun Pharmaceutical Industries LimitedNCT05422911Written as Apalutamide
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted2
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerNov 9, 2026NCT03009981
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyOct 19, 2026NCT05960578
Stopped1
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyTerminatedOct 19, 2026NCT05960578
Codes
What other systems call apalutamide · ClinicalTrials.gg INT006056
- MeSH (NLM) C572045apalutamideOne source ClinicalTrials.gov
- UNII (FDA) 4T36H88UA7APALUTAMIDEConfirmed FDA, Wikidata
- RxNorm 1999574Confirmed FDA, Wikidata
- Wikidata Q21098975apalutamideConfirmed FDA, Wikidata
- NCI Thesaurus C92574ApalutamideOne source FDA
- DrugBank DB11901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572045 | apalutamide | One source ClinicalTrials.gov |
| UNII (FDA) | 4T36H88UA7 | APALUTAMIDE | Confirmed FDA, Wikidata |
| RxNorm | 1999574 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21098975 | apalutamide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C92574 | Apalutamide | One source FDA |
| DrugBank | DB11901 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.